Epigenetische Modifikationen
in malignen Zellen

B Hackanson; M Lübbert

doi:10.1055/s-0031-1274530

DMW - Deutsche Medizinische Wochenschrift, Table of Contents

Dtsch Med Wochenschr 2011; 136(10): 475-479
DOI: 10.1055/s-0031-1274530

Prinzip & Perspektive | Review article

Genetik, Hämatologie
© Georg Thieme Verlag KG Stuttgart · New York

Epigenetische Modifikationen in malignen Zellen

Relevanz für die Therapie von myelodysplastischem Syndrom und akuter myeloischer LeukämieEpigenetic changes in malignant cellsRelevance for the treatment of myelodysplastic syndrome and acute myeloic leukemiaB. Hackanson¹ , M. Lübbert¹

¹Medizinische Universitätsklinik Freiburg, Abteilung Hämatologie und Onkologie, Freiburg

Abstract

Schlüsselwörter

Epigenetik - DNA-Methylierung - Histone

Keywords

epigenetics - DNA methylisation - histones

Full Text

References

Literatur

1 Almstedt M, Blagitko-Dorfs N, Duque-Afonso J. et al . The DNA demethylating agent 5-aza-2’- deoxycytidine induces expression of NY-ESO-1 and other cancer/testis antigens in myeloid leukemia cells. Leuk Res. 2010; 34 899-905
2 Borthakur G, Ahdab S E, Ravandi F. et al . Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine. Leuk Lymphoma. 2008; 49 690-695
3 Cashen A F, Schiller G J, O’Donnell M R, DiPersio J F. Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia. Clin Oncol. 2010; 28 556-561
4 Fenaux P, Mufti G J, Hellström-Lindberg E. et al . Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol. 2010; 28 562-569
5 Fenaux P, Mufti G J, Hellström-Lindberg E. et al . Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009; 10 223-232
6 Field T, Perkins J, Huang Y. et al . 5-Azacitidine for myelodysplasia before allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2010; 45 255-260
7 Flotho C, Claus R, Batz C. et al . The DNA methyltransferase inhibitors azacitidine, Decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells. Leukemia. 2009; 23 1019-1028
8 Garcia-Manero G, Yang H, Bueso-Ramos C. et al . Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood. 2008; 111 1060-1066
9 Goodyear O, Agathanggelou A, Novitzky-Basso I. et al . Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia. Blood. 2010; 116 1908-1918
10 Hackanson B, Guo Y, Lübbert M. The silence of the genes: epigenetic disturbances in haematopoietic malignancies. Expert Opin Ther Targets. 2005; 9 45-61
11 Issa J-P J, Kantarjian H M. Targeting DNA methylation. Clin Cancer Res. 2009; 15 3938-3946
12 Kantarjian H, Issa J P, Rosenfeld C S. et al . Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer. 2006; 106 1794-1803
13 Kornblith A B, Herndon 2nd J E, Silverman L R. et al . Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study. J Clin Oncol. 2002; 20 2441-2452
14 Kuendgen A, Schmid M, Schlenk R. et al . The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia. Cancer. 2006; 106 112-119
15 Ley T J, Ding L, Walter M J. et al . DNMT3A mutations in acute myeloid leukemia. N Engl J Med. 2010; 363 2424-2433
16 Lübbert M, Bertz H, Rüter B. et al . Non-intensive treatment with low-dose 5-aza-2’- deoxycytidine (DAC) prior to allogeneic blood SCT of older MDS/AML patients. Bone Marrow Transplant. 2009; 44 585-588
17 Lübbert M, Suciu S, Baila L. et al . Low-dose decitabine vs. best supportive care in elderly patients with intermediate- or high-risk MDS ineligible for intensive chemotherapy: final results of the randomized phase III study of the EORTC Leukemia Group and the German MDS Study Group. J Clin Oncol. in press 2011
18 Marcucci G, Haferlach T, Döhner H. Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications. J Clin Oncol. 2011; 29 475-486
19 Möller I, Blum S, Gattermann N at al. Repeated responses of an elderly patient with high-risk myelodysplastic syndrome to sequential therapy with tipifarnib, 5-azacitidine, and decitabine. Ann Hematol. 2009; 88 1141-1144
20 Silverman L R, Demakos E P, Peterson B L. et al . Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol. 2002; 20 2429-2440
21 Wagner J, Hackanson B, Lübbert M. et al . Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy. Clin Epigenet. 2010; 1 117-136

Dr. med. Björn Hackanson

Medizinische Universitätsklinik Freiburg
Abteilung Hämatologie und Onkologie

Hugstetter Str. 55

79106 Freiburg

Phone: 0761/2707715

Email: bjoern.hackanson@uniklinik-freiburg.de